Seed Therapeutics

Seed Therapeutics

  • Founded: 2019
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: NEU, ONC, INF
  • Lead product: Undisclosed
  • Product link:
  • Funding: 10-50M

job board

Short description:

Molecular glues - therapeutics that degrade disease-causing, undruggable proteins

Drug notes:

6 additional undisclosed programs RD oncology, neurodegeneration, viral infection

Long description:

Seed Therapeutics is developing molecular glues to degrade disease-causing proteins. Targeted protein degradation is a cellular mechanism that enables specific proteins to be destroyed through the use of ubiquitin E3 ligases. E3 ligases provide specificity by recognising chains of ubiquitin marks on proteins. Seed is exploiting this mechanism to reduce the amount of disease-causing proteins - such as oncogenes - that are frequently overexpressed or over-activated in cancer. To achieve this, Seed is using their understanding of “molecular glues” to induce ubiquitin E3 ligases to bind dysfunctional proteins that it normally would not. Currently, Seed is focusing on neurodegeneration and cancer targets, including the oncogene KRAS.


Seed Therapeutics
Research Scientist - Drug Screening
King of Prussia, PA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy